Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Growth Hormone Axis

SERMORELIN

The original GHRH peptide. Tells your own pituitary to release a natural pulse of growth hormone, you make your own GH rather than injecting it.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

The original GHRH peptide.

Tells your own pituitary to release a natural pulse of growth hormone, you make your own GH rather than injecting it.

What It Does

Sermorelin is GHRH(1–29), the active fragment of growth-hormone-releasing hormone.

It binds pituitary GHRH receptors and triggers a physiological GH pulse that is still regulated by your own feedback loop (somatostatin), so it rarely overshoots.

Was FDA-approved as Geref for pediatric GH deficiency / GH-axis testing (discontinued 2008); now compounded off-label for adults.

Reconstitution

Vial SizeBAC Water / SolventConcentration
2 mg+ 0.4 mL5 mg/mL
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–2Nightly 5×/week200 mcg5.0u Start low; assess sleep and tolerance before increasing.
Weeks 3–12Nightly 5×/week300 mcg7.5u Standard effective dose. Often paired with a GHRP for a larger combined pulse.
Off4 weeks–– Let the pituitary and receptors recover before the next cycle.
Cycle & Timing

8–12 weeks on / 4 weeks off.

Timing

Fasted pre-bed (largest natural GH pulse is during deep sleep). No food 60–90 min before / 60 min after, carbs and fats blunt the pulse.

Evidence Context

human-validated (former FDA drug Geref); very short half-life (~10–20 min) so consistent nightly dosing matters.

Population Considerations

Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable. Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable. Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the top.

Handling & Stacking

Injection site
SubQ, abdomen preferred. Rotate.
Storage
Freeze-dried: -4°F. Reconstituted: 36–46°F. Best used within 28 days, otherwise potency gradually fades over ~3–4 weeks (structure-based estimate, no published data).
Side effects
Injection-site flushing/warmth, occasional headache, mild water retention. Self-limiting feedback makes overshoot uncommon.
What to expect
  • Deeper sleep within 1–2 weeks; recovery and body-composition changes over 8–12 weeks.
  • Gentler and more physiological than injected HGH.
  • Supply math 2mg → 9 vials | 5mg → 4 vials | 10mg → 2 vials (12-wk @ 300 mcg × 5/wk)
Pairs well with
Ipamorelin (canonical GHRH + GHRP pulse synergy); CJC-1295 (No DAC); Wolverine Blend (BPC-157 + TB-500) (recovery)
Avoid
Active malignancy. Severe insulin resistance. Combining multiple GHRH analogs at once
Approved drug
Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Safety & Patient Education

Contraindications
Active malignancy of any kind (GH/IGF-1 can promote tumor growth) Severe diabetic retinopathy Acute critical illness (per somatropin label, applies to GH-axis stimulators) Pregnancy and lactation
Warnings
Insulin resistance / worsening glycemic control with sustained use Fluid retention, peripheral edema, carpal tunnel with extended use Joint and muscle pain IGF-1 elevation: theoretical malignancy promotion if pushed beyond physiological ranges More self-limiting than direct HGH (feedback-regulated), but class warnings still apply
Drug interactions
Glucocorticoids: blunt GH response, minimize or time away from injection Insulin / antidiabetics: GH worsens insulin resistance, expect dose adjustments + tighter monitoring Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1; transdermal doesn’t
Labs
  • IGF-1 (baseline + Week 8 + end).
  • Target upper-normal for age Fasting glucose and HbA1c (baseline + end of cycle) Age-appropriate cancer screening before starting Out of range?
  • IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.
Stop criteria
Fasting glucose rises >20 mg/dL above baseline IGF-1 rises above the upper limit of normal for age New persistent joint pain or carpal tunnel symptoms New skin changes or enlarging moles; vision changes
Patient education
You are stimulating your own GH, not replacing it; effects build gradually Most GH is released in deep sleep, dose pre-bed and protect sleep Food within 90 min blunts the pulse, fasted is standard Not for use during active malignancy or pregnancy; report new lumps or vision changes
References
researchdosing · peptidedosages · PubMed · thepeptidereport · Span 2000 · Weissberger 1991